New antibiotics targeting MDR pathogens are expensive, but not impressive
The U.S. Food and Drug Administration has approved a number of new antibiotics targeting multidrug-resistant bacteria in the past 5 years, but the new drugs have not led to a substantial improvement...
Source: Pediatric News - Category: Journals (General) Source Type: news
More News: Food and Drug Administration (FDA) | General Medicine | Multidrug Resistance | Pediatrics